Asthma: personalized and precision medicine

Giorgio W. Canonica, Matteo Ferrando, Ilaria Baiardini, Francesca Puggioni, Francesca Racca, Giovanni Passalacqua, Enrico Heffler

Research output: Contribution to journalArticle

Abstract

Purpose of review In this review, we herein describe the progress in management of severe asthma, evolving from a 'blockbuster approach' to a more personalized approach targeted to the utilization of endotype-driven therapies. Recent findings Severe asthma characterization in phenotypes and endotypes, by means of specific biomarkers, have led to the dichotomization of the concepts of 'personalized medicine' and 'precision medicine', which are often used as synonyms, but actually have conceptual differences in meaning. The recent contribute of the omic sciences (i.e. proteomics, transcriptomics, metabolomics, genomics,...) has brought this initially theoretic evolution into a more concrete level. Summary This step-by-step transition would bring to a better approach to severe asthmatic patients as the personalization of their therapeutic strategy would bring to a better patient selection, a more precise endotype-driven treatment, and hopefully to better results in terms of reduction of exacerbation rates, symptoms, pulmonary function and quality of life.
Original languageEnglish
Pages (from-to)51-58
Number of pages8
JournalCurrent Opinion in Allergy and Clinical Immunology
Volume18
Issue number1
DOIs
Publication statusPublished - Feb 1 2018

Fingerprint

Precision Medicine
Asthma
Metabolomics
Genomics
Proteomics
Patient Selection
Therapeutics
Biomarkers
Quality of Life
Phenotype
Lung

Keywords

  • biological therapies
  • biomarkers
  • personalized medicine
  • precision medicine
  • severe asthma

Cite this

Asthma: personalized and precision medicine. / Canonica, Giorgio W.; Ferrando, Matteo; Baiardini, Ilaria; Puggioni, Francesca; Racca, Francesca; Passalacqua, Giovanni; Heffler, Enrico.

In: Current Opinion in Allergy and Clinical Immunology, Vol. 18, No. 1, 01.02.2018, p. 51-58.

Research output: Contribution to journalArticle

Canonica, Giorgio W. ; Ferrando, Matteo ; Baiardini, Ilaria ; Puggioni, Francesca ; Racca, Francesca ; Passalacqua, Giovanni ; Heffler, Enrico. / Asthma: personalized and precision medicine. In: Current Opinion in Allergy and Clinical Immunology. 2018 ; Vol. 18, No. 1. pp. 51-58.
@article{6ccfd0cce5c84c039943bd9cea36872d,
title = "Asthma:: personalized and precision medicine",
abstract = "Purpose of review In this review, we herein describe the progress in management of severe asthma, evolving from a 'blockbuster approach' to a more personalized approach targeted to the utilization of endotype-driven therapies. Recent findings Severe asthma characterization in phenotypes and endotypes, by means of specific biomarkers, have led to the dichotomization of the concepts of 'personalized medicine' and 'precision medicine', which are often used as synonyms, but actually have conceptual differences in meaning. The recent contribute of the omic sciences (i.e. proteomics, transcriptomics, metabolomics, genomics,...) has brought this initially theoretic evolution into a more concrete level. Summary This step-by-step transition would bring to a better approach to severe asthmatic patients as the personalization of their therapeutic strategy would bring to a better patient selection, a more precise endotype-driven treatment, and hopefully to better results in terms of reduction of exacerbation rates, symptoms, pulmonary function and quality of life.",
keywords = "biological therapies, biomarkers, personalized medicine, precision medicine, severe asthma",
author = "Canonica, {Giorgio W.} and Matteo Ferrando and Ilaria Baiardini and Francesca Puggioni and Francesca Racca and Giovanni Passalacqua and Enrico Heffler",
year = "2018",
month = "2",
day = "1",
doi = "10.1097/ACI.0000000000000416",
language = "English",
volume = "18",
pages = "51--58",
journal = "Current Opinion in Allergy and Clinical Immunology",
issn = "1528-4050",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Asthma:

T2 - personalized and precision medicine

AU - Canonica, Giorgio W.

AU - Ferrando, Matteo

AU - Baiardini, Ilaria

AU - Puggioni, Francesca

AU - Racca, Francesca

AU - Passalacqua, Giovanni

AU - Heffler, Enrico

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Purpose of review In this review, we herein describe the progress in management of severe asthma, evolving from a 'blockbuster approach' to a more personalized approach targeted to the utilization of endotype-driven therapies. Recent findings Severe asthma characterization in phenotypes and endotypes, by means of specific biomarkers, have led to the dichotomization of the concepts of 'personalized medicine' and 'precision medicine', which are often used as synonyms, but actually have conceptual differences in meaning. The recent contribute of the omic sciences (i.e. proteomics, transcriptomics, metabolomics, genomics,...) has brought this initially theoretic evolution into a more concrete level. Summary This step-by-step transition would bring to a better approach to severe asthmatic patients as the personalization of their therapeutic strategy would bring to a better patient selection, a more precise endotype-driven treatment, and hopefully to better results in terms of reduction of exacerbation rates, symptoms, pulmonary function and quality of life.

AB - Purpose of review In this review, we herein describe the progress in management of severe asthma, evolving from a 'blockbuster approach' to a more personalized approach targeted to the utilization of endotype-driven therapies. Recent findings Severe asthma characterization in phenotypes and endotypes, by means of specific biomarkers, have led to the dichotomization of the concepts of 'personalized medicine' and 'precision medicine', which are often used as synonyms, but actually have conceptual differences in meaning. The recent contribute of the omic sciences (i.e. proteomics, transcriptomics, metabolomics, genomics,...) has brought this initially theoretic evolution into a more concrete level. Summary This step-by-step transition would bring to a better approach to severe asthmatic patients as the personalization of their therapeutic strategy would bring to a better patient selection, a more precise endotype-driven treatment, and hopefully to better results in terms of reduction of exacerbation rates, symptoms, pulmonary function and quality of life.

KW - biological therapies

KW - biomarkers

KW - personalized medicine

KW - precision medicine

KW - severe asthma

U2 - 10.1097/ACI.0000000000000416

DO - 10.1097/ACI.0000000000000416

M3 - Article

VL - 18

SP - 51

EP - 58

JO - Current Opinion in Allergy and Clinical Immunology

JF - Current Opinion in Allergy and Clinical Immunology

SN - 1528-4050

IS - 1

ER -